Apelin C-terminal fragments: biological properties and therapeutic potential

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Тек жазылушылар үшін

Аннотация

The creation of bioactive molecules for the treatment of cardiovascular diseases based on natural peptides stimulates intensive experimental research. In recent years, it has been established that the C-terminal fragments of apelin, an endogenous ligand of the APJ receptor, reduce metabolic and functional disorders in experimental heart damage. The review presents literature data and generalized results of our own experiments on the effect of apelin-13, [Pyr]apelin-13, apelin-12, and their chemically modified analogues on the heart in normal conditions and when modeling pathophysiological conditions in vitro and in vivo. It has been shown that the spectrum of action of apelin peptides on the damaged myocardium covers a decrease in the death of cardiomyocytes from necrosis, a decrease in cardiomyocyte membrane damage, an improvement in the metabolic state of the myocardium, and a decrease in the formation of reactive oxygen species and lipid peroxidation products. The mechanisms of the protective action of these peptides associated with the activation of the APJ receptor and the manifestation of antioxidant properties are discussed. The data presented in the review indicate the promise of molecular design of pharmacological APJ receptor agonists, which can serve as the basis for the development of cardioprotectors that affect the processes of free radical oxidation and metabolic adaptation.

Авторлар туралы

O. Pisarenko

National Medical Research Center of Cardiology named after Academician E. I. Chazov

Email: olpi@live.ru
121552 Moscow, Russia

I. Studneva

National Medical Research Center of Cardiology named after Academician E. I. Chazov

121552 Moscow, Russia

Әдебиет тізімі

  1. Coelho, M., Oliveira, T., and Fernandes, R. (2013) Biochemistry of adipose tissue: an endocrine organ, Arch. Med. Sci., 9, 191-200, doi: 10.5114/aoms.2013.33181.
  2. Castan-Laurell, I., Masri, B., and Valet, P. (2019) The apelin/APJ system as a therapeutic target in metabolic diseases, Expert. Opin. Ther. Targets, 23, 215-225, doi: 10.1080/14728222.2019.1561871.
  3. Kinjo, T., Higash, H., Un, K., and Kuramoto, N. (2021) Apelin/apelin receptor system molecular characteristics, physiological roles, and prospects as a target for disease prevention and pharmacotherapy, Curr. Mol. Pharmacol., 14, 210-221, doi: 10.2174/1874467213666200602133032.
  4. O'Dowd, B. F., Heiber, M., Chan, A., Heng, H. H., Tsui, L. C., Kennedy, J. L., Shi, X., Petronis, A., George, S. R., and Nguyen, T. (1993) A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11, Gene, 136, 355-360, doi: 10.1016/0378-1119(93)90495-o.
  5. Cai, X., Bai, B., Zhang, R., Wang, Ch., and Chen, J. (2017) Apelin receptor homodimer-oligomers revealed by single-molecule imaging and novel G protein-dependent signaling, Sci. Rep., 7, 40335, doi: 10.1038/srep40335.
  6. Charo, D. N., Ho, M., Fajardo, G., Kawana, M., Kundu, R. K., Sheikh, A. Y., Finsterbach, Th. P., Leeper, N. J., Ernst, K. V., Chen, M. M., Ho, Y. D., Chun, H. J., Bernstein, D., Ashley, E. A., and Quertermous, Th. (2009) Endogenous regulation of cardiovascular function by apelin-APJ, Am. J. Physiol. Heart Circ. Physiol., 297, 1904-1913, doi: 10.1152/ajpheart.00686.2009.
  7. Li, Y., Chen, J., Bai, B., Du, H., Liu, Y., and Liu, H. (2012) Heterodimerization of human apelin and kappa opioid receptors: roles in signal transduction, Cell Signal., 24, 991-1001, doi: 10.1016/j.cellsig.2011.12.012.
  8. Abbasloo, E., Najafipour, H., and Esmaeili-Mahani, S. (2016) Induction of antinociceptive tolerance to the chronic intrathecal administration of apelin-13 in rat, Neuropeptides, 60, 7-12, doi: 10.1016/j.npep.2016.08.001.
  9. Tatemoto, K., Hosoya, M., Habata, Y., Fujii, R., Kakegawa, T., Zou, M. X., Kawamata, Y., Fukusumi, S., Hinuma, S., Kitada, C., Kurokawa, T., Onda, H., and Fujino, M. (1998) Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor, Biochem. Biophys. Res. Commun., 251, 471-476, doi: 10.1006/bbrc.1998.9489.
  10. Kawamata, Y., Habata, Y., Fukusumi, S., Hosoya, M., Fujii, R., Hinuma, S., Nishizawa, N., Kitada, C., Onda, H., Nishimura, O., and Fujino, M. (2001) Molecular properties of apelin: tissue distribution and receptor binding, Biochim. Biophys. Acta, 1538, 162-171, doi: 10.1016/s0167-4889(00)00143-9.
  11. Roberts, E. M., Newson, M. J. F., Pope, G. R., Landgraf, R., Lolait, S. J., and O'Carroll, A. M. (2009) Abnormal fluid homeostasis in apelin receptor knockout mice, J. Endocrinol., 202, 453-462, doi: 10.1677/JOE-09-0134.
  12. Mughal, A., and O'Rourke, S. T. (2018) Vascular effects of apelin: mechanisms and therapeutic potential. Pharmacol. Ther., 190, 139-147, doi: 10.1016/j.pharmthera.2018.05.013.
  13. Bertrand, C., Valet, P., and Castan-Laurell, I. (2015) Apelin and energy metabolism, Front. Physiol., 6, 115, doi: 10.3389/fphys.2015.00115.
  14. Chung, S. C., Ho, L., Tian, J., and Reversade, B. (2013) ELABELA: a hormone essential for heart development signals via the Apelin receptor, Dev. Cell., 27, 672-680, doi: 10.1016/j.devcel.2013.11.002.
  15. Lee, D. K., Cheng, R., Nguyen, T., Fan, T., Kariyawasam, A. P., Liu, Y., Osmond, D. H., George, S. R., and O'Dowd, B. F. (2000) Characterization of apelin, the ligand for the APJ receptor, J. Neurochem., 74, 34-41, doi: 10.1074/jbc.M908417199.
  16. Hosoya, M., Kawamata, Y., Fukusumi, S., Fujii, R., Habata, Y., Hinuma, S., Kitada, C., Honda, S., Kurokawa, T., Onda, H., Nishimura, O., and Fujino, M. (2000) Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin, J. Biol. Chem., 275, 21061-21067, doi: 10.1074/jbc.M908417199.
  17. Kleinz, M. J., and Davenport, A. P. (2005) Emerging roles of apelin in biology and medicine, Pharmacol. Ther., 107, 198-211, doi: 10.1016/j.pharmthera.2005.04.001.
  18. Japp, A. G., and Newby, D. E. (2016) Unlocking the therapeutic potential of apelin, Hypertension, 68, 307-309, doi: 10.1161/HYPERTENSIONAHA.116.07057.
  19. Shin, K., Chapman, N. A., Sarker, M., Kenward, C., Huang, S. K., Weatherbee-Martin, N., Pandey, A., Dupré, D. J., and Rainey, J. K. (2017) Bioactivity of the putative apelin proprotein expands the repertoire of apelin receptor ligands, Biochim. Biophys. Acta Gen. Sub., 1861, 1901-1912, doi: 10.1016/j.bbagen.2017.05.017.
  20. Shin, K., Pandey, A., Liu, X. Q., Anini, Y., and Rainey, J. K. (2013) Preferential apelin-13 production by the proprotein convertase PCSK3 is implicated in obesity, FEBS Open Bio., 3, 328-333, doi: 10.1016/j.fob.2013.08.001.
  21. Adam, F., Khatib, A. M., Lopez, J. J., Vatier, C., Turpin, S., Muscat, A., Soulet, F., Aries, A., Jardin, I., Bobe, R., Stepanian, A., de Prost, D., Dray, C., Rosado, J. A., Valet, P., Feve, B., and Siegfried, G. (2016) Apelin: an antithrombotic factor that inhibits platelet function, Blood, 127, 908-920, doi: 10.1182/blood-2014-05-578781.
  22. McKinnie, S. M., Fischer, C., Tran, K. M., Wang, W., Mosquera, F., Oudit, G. Y., and Vederas, J. C. (2016) The metalloprotease neprilysin degrades and inactivates apelin peptides, Chem. Bio. Chem., 17, 1495-1498, doi: 10.1002/cbic.201600244.
  23. Vickers, C., Hales, P., Kaushik, V., Dick, L., Gavin, J., Tang, J., Godbout, K., Parsons, T., Baronas, E., Hsieh, F., Acton, S., Patane, M., Nichols, A., and Tummino, P. (2002) Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase, J. Biol. Chem., 277, 14838-14843, doi: 10.1074/jbc.M200581200.
  24. Kehoe, K., Elzen, R., Verkerk, R., Sima, Y., van der Veken, P., Lambeir, A. M., and De Meester, I. (2016) Prolyl carboxypeptidase purified from human placenta: its characterization and identification as an apelin-cleaving enzyme, Biochim. Biophys. Acta, 1864, 1481-1488, doi: 10.1016/j.bbapap.2016.07.004.
  25. Fischer, C., Lamer, T., Wang, W., McKinnie, S. M. K., Iturrioz, X., Llorens-Cortes, C., Oudit, G. Y., and Vederas, J. C. (2019) Plasma kallikrein cleaves and inactivates apelin-17: palmitoyl- and PEG-extended apelin-17 analogs as metabolically stable blood pressure-lowering agents, Eur. J. Med. Chem., 166, 119-124, doi: 10.1016/j.ejmech.2019.01.040.
  26. Ma, Y., Yue, Y., Ma, Y., Zhang, Q., Zhou, Q., Song, Y., Shen, Y., Li, X., Ma, X., Li, C., Hanson, M. A., Han, G. W., Sickmier, E. A., Swaminath, G., Zhao, S., Stevens, R. C., Hu, L. A., Zhong, W., Zhang, M., and Xu, F. (2017) Structural basis for apelin control of the human apelin receptor, Structure, 25, 858-866.e4, doi: 10.1016/j.str.2017.04.008.
  27. Medhurst, A. D., Jennings, C. A., Robbins, M. J., Davis, R. P., Ellis, C., Winborn, K. Y., Lawrie, K. W., Hervieu, G., Riley, G., Bolaky, J. E., Herrity, N. C., Murdock, P., and Darker, J. G. (2003) Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin, J. Neurochem., 84, 1162-1172, doi: 10.1046/j.1471-4159.2003.01587.x.
  28. Langelan, D. N., Bebbington, E. M., Reddy, T., and Rainey, J. K. (2009) Structural insight into G-protein coupled receptor binding by apelin, Biochemistry, 48, 537-548, doi: 10.1021/bi801864b.
  29. Tyndall, J. D., Pfeiffer, B., Abbenante, G., and Fairlie, D. P. (2005) Over one hundred peptide-activated G protein-coupled receptors recognize ligands with turn structure, Chem. Rev., 105, 793-826, doi: 10.1021/cr040689g.
  30. Murza, A., Parent, A., Besserer-Offroy, E., Tremblay, H., Karadereye, F., Beaudet, N., Leduc, R., Sarret, P., and Marsault, É. (2012) Elucidation of the structure-activity relationships of apelin: influence of unnatural amino acids on binding, signaling, and plasma stability, Chem. Med. Chem., 7, 318-325, doi: 10.1002/cmdc.201100492.
  31. Kleinz, M. J., and Davenport, A. P. (2004) Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells, Regul. Pept., 118, 119-125, doi: 10.1016/j.regpep.2003.11.002.
  32. Kleinz, M. J., Skepper, J. N., and Davenport, A. P. (2005) Immunocytochemical localization of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells, Regul. Pept., 126, 233-240, doi: 10.1016/j.regpep.2004.10.019.
  33. Barnes, G., Japp, A. G., and Newby, D. E. (2010) Translational promise of the apelin-APJ system, Heart, 96, 1011-1016, doi: 10.1136/hrt.2009.191122.
  34. Chapman, N. A., Dupré, D. J., and Rainey, J. K. (2024) The apelin receptor: physiology, pathology, cell signalling, and ligand modulation of a peptide-activated class A GPCR, Biochem. Cell Biol., 92, 431-440, doi: 10.1139/bcb-2014-0072.
  35. Pitkin, S. L., Maguire, J. J., Bonner, T. I., and Davenport, A. P. (2010) International union of basic and clinical pharmacology. LXXIV. Apelin receptor nomenclature, distribution, pharmacology, and function, Pharmacol. Rev., 62, 331-342, doi: 10.1124/pr.110.002949.
  36. Tatemoto, K., Takayama, K., Zou, M. X., Kumaki, I., Zhang, W., Kumano, K., and Fujimiya, M. (2001) The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism, Regul. Pept., 99, 87-92, doi: 10.1016/s0167-0115(01)00236-1.
  37. Japp, A. G., Cruden, N. L., Amer, D. A., Li, V. K., Goudie, E. B., Johnston, N. R., Sharma, S., Neilson, I., Webb, D. J., Megson, I. L., Flapan, A. D., and Newby, D. E. (2008) Vascular effects of apelin in vivo in man, Am. Coll. Cardiol., 52, 908-913, doi: 10.1016/j.jacc.2008.06.013.
  38. Salcedo, A., Garijo, J., Monge, L., Fernandez, N., Luis García-Villalon, A., Sánchez Turrión, V., Cuervas-Mons, V., and Diéguez, G. (2007) Apelin effects in human splanchnic arteries. Role of nitric oxide and prostanoids, Regul. Pept., 144, 50-55, doi: 10.1016/j.regpep.2007.06.005.
  39. Katugampola, S. D., Maguire, J. J., Matthewson, S. R., and Davenport, A. P. (2001) [125I]-(Pyr1)Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man, Br. J. Pharmacol., 132, 1255-1260, doi: 10.1038/sj.bjp.0703939.
  40. Maguire, J. J., Kleinz, M. J., Pitkin, S. L., and Davenport, A. P. (2009) [Pyr1]apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease, Hypertension, 54, 598-604, doi: 10.1161/HYPERTENSIONAHA.109.134619.
  41. Kasai, A., Shintani, N., Oda, M., Kakuda, M., Hashimoto, H., Matsuda, T., Hinuma, S., and Baba, A. (2004) Apelin is a novel angiogenic factor in retinal endothelial cells, Biochem. Biophys. Res. Commun., 325, 395-400, doi: 10.1016/j.bbrc.2004.10.042.
  42. Cox, C. M., D'Agostino, S. L., Miller, M. K., Heimark, R. L., and Krieg, P. A. (2006) Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo, Dev. Biol., 296, 177-189, doi: 10.1016/j.ydbio.2006.04.452.
  43. Masri, B., Morin, N., Cornu, M., Knibiehler, B., and Audigier, Y. (2004) Apelin (65-77) activates p70S6 kinase and is mitogenic for umbilical endothelial cells, FASEB J., 18, 1909-1911, doi: 10.1096/fj.04-1930fje.
  44. Li, F., Li, L., Qin, X., Pan, W., Feng, F., Chen, F., Zhu, B., Liao, D., Tanowitz, H., Albanese, C., and Chen, L. (2008) Apelin-induced vascular smooth muscle cell proliferation: the regulation of cyclin D1, Front. Biosci., 13, 3786-3792, doi: 10.2741/2967.
  45. Kasai, A., Shintani, N., Kato, H., Matsuda, S., Gomi, F., Haba, R., Hashimoto, H., Kakuda, M., Tano, Y., and Baba, A. (2008) Retardation of retinal vascular development in apelin deficient mice, Arterioscler. Thromb. Vasc. Biol., 28, 1717-1722, doi: 10.1161/ATVBAHA.108.163402.
  46. Zhang, Q., Shen, Y., Niloy, S. I., O'Rourke, S. T., and Sun, C. (2023) Chronic effects of apelin on cardiovascular regulation and angiotensin II-induced hypertension, Pharmaceuticals (Basel), 16, 600, doi: 10.3390/ph16040600.
  47. Berry, M. F., Pirolli, T. J., Jayasankar, V., Burdick, J., Morine, K. J., Gardner, T. J., and Woo, Y. J. (2004) Apelin has in vivo inotropic effects on normal and failing hearts, Circulation, 110, II187-II193, doi: 10.1161/01.CIR.0000138382.57325.5c.
  48. Aydin, S., Eren, M. N., Sahin, I., and Aydin, S. (2014) The role of apelins in the physiology of the heart, Protein Pept. Lett., 21, 2-9, doi: 10.2174/09298665113209990083.
  49. Szokodi, I., Tavi, P., Földes, G., Voutilainen-Myllylä, S., Ilves, M., Tokola, H., Pikkarainen, S., Piuhola, J., Rysä, J., Tóth, M., and Ruskoaho, H. (2002) Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility, Circ. Res., 91, 434-440, doi: 10.1161/01.res.0000033522.37861.69.
  50. Ashley, E. A., Powers, J., Chen, M., Kundu, R., Finsterbach, T., Caffarelli, A., Deng, A., Eichhorn, J., Mahajan, R., Agrawal, R., Greve, J., Robbins, R., Patterson, A. J., Bernstein, D., and Quertermous, T. (2005) The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo, Cardiovasc. Res., 65, 73-82, doi: 10.1016/j.cardiores.2004.08.018.
  51. Scimia, M. C., Hurtado, C., Ray, S., Metzler, S., Wei, K., Wang, J., Woods, C. E., Purcell, N. H., Catalucci, D., Akasaka, T., Bueno, O. F., Vlasuk, G. P., Kaliman, P., Bodmer, R., Smith, L. H., Ashley, E., Mercola, M., Brown, J. H., and Ruiz-Lozano, P. (2012) APJ acts as a dual receptor in cardiac hypertrophy, Nature, 488, 394-398, doi: 10.1038/nature11263.
  52. De Mota, N., Reaux-Le Goazigo, A., El Messari, S., Chartrel, N., Roesch, D., Dujardin, C., Kordon, C., Vaudry, H., Moos, F., and Llorens-Cortes, C. (2004) Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release, Proc. Natl. Acad. Sci. USA, 101, 10464-10469, doi: 10.1073/pnas.0403518101.
  53. Reaux-Le Goazigo, A., Morinville, A., Burlet, A., Llorens-Cortes, C., and Beaudet, A. (2004) Dehydration-induced cross-regulation of apelin and vasopressin immunoreactivity levels in magnocellular hypothalamic neurons, Endocrinology, 145, 4392-4400, doi: 10.1210/en.2004-0384.
  54. Huang, Zh., Luo, X., Liu, M., and Chen, L. (2019) Function and regulation of apelin/APJ system in digestive physiology and pathology, J. Cell. Physiol., 234, 7796-7810, doi: 10.1002/jcp.27720.
  55. Kunduzova, O., Alet, N., Delesque-Touchard, N., Millet, L., Castan-Laurell, I., Muller, C., Dray, C., Schaeffer, P., Herault, J. P., Savi, P., Bono, F., and Valet, P. (2008) Apelin/APJ signaling system: a potential link between adipose tissue and endothelial angiogenic processes, FASEB J., 22, 4146-4153, doi: 10.1096/fj.07-104018.
  56. Wei, L., Hou, X., and Tatemoto, K. (2005) Regulation of apelin mRNA expression by insulin and glucocorticoids in mouse 3T3-L1 adipocytes, Regul. Pept., 132, 27-32, doi: 10.1016/j.regpep.2005.08.003.
  57. Sorhede Winzell, M., Magnusson, C., and Ahren, B. (2005) The APJ receptor is expressed in pancreatic islets and its ligand, apelin, inhibits insulin secretion in mice, Regul. Pept., 131, 12-17, doi: 10.1016/j.regpep.2005.05.004.
  58. Dray, C., Knauf, C., Daviaud, D., Waget, A., Boucher, J., Buléon, M., Cani, P. D., Attané, C., Guigné, C., Carpéné, C., Burcelin, R., Castan-Laurell, I., and Valet, P. (2008) Apelin stimulates glucose utilization in normal and obese insulin-resistant mice, Cell. Metab., 8, 437-445, doi: 10.1016/j.cmet.2008.10.003.
  59. Castan-Laurell, I., Vítkova, M., Daviaud, D., Dray, C., Kováciková, M., Kovacova, Z., Hejnova, J., Stich, V., and Valet, P. (2008) Effect of hypocaloric diet-induced weight loss in obese women on plasma apelin and adipose tissue expression of apelin and APJ, Eur. J. Endocrinol., 158, 905-910, doi: 10.1530/EJE-08-0039.
  60. Li, L., Yang, G., Li, Q., Tang, Y., Yang, M., Yang, H., and Li, K. (2006) Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects, Exp. Clin. Endocrinol. Diab., 114, 544-548, doi: 10.1055/s-2006-948309.
  61. Castan-Laurell, I., Dray, C., Knauf, C., Kunduzova, O., and Valet, P. (2012) Apelin, a promising target for type 2 diabetes treatment? Trends. Endocrinol. Metab., 23, 234-241, doi: 10.1016/j.tem.2012.02.005.
  62. Yue, P., Jin, H., Aillaud, M., Deng, A. C., Azuma, J., Asagami, T., Kundu, R. K., Reaven, G. M., Quertermous, T., and Tsao, P. S. (2010) Apelin is necessary for the maintenance of insulin sensitivity, Am. J. Physiol. Endocrinol. Metab., 298, E59-E67, doi: 10.1152/ajpendo.00385.2009.
  63. Higuchi, K., Masaki, T., Gotoh, K., Chiba, S., Katsuragi, I., Tanaka, K., Kakuma, T., and Yoshimatsu, H. (2007) Apelin, an APJ receptor ligand, regulates body adiposity and favors the messenger ribonucleic acid expression of uncoupling proteins in mice, Endocrinology, 148, 2690-2697, doi: 10.1210/en.2006-1270.
  64. Chen, M. M., Ashley, E. A., Deng, D. X., Tsalenko, A., Deng, A., Tabibiazar, R., Ben-Dor, A., Fenster, B., Yang, E., King, J. Y., Fowler, M., Robbins, R., Johnson, F. L., Bruhn, L., McDonagh, T., Dargie, H., Yakhini, Z., Tsao, P. S., and Quertermous, T. (2003) Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction, Circulation, 108, 12, 1432-1439, doi: 10.1161/01.CIR.0000091235.94914.75.
  65. Chong, K. S., Gardner, R. S., Morton, J. J., Ashley, E. A., and McDonagh, T. A. (2006) Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure, Eur. J. Heart. Fail., 8, 355-360, doi: 10.1016/j.ejheart.2005.10.007.
  66. Miettinen, K. H., Magga, J., Vuolteenaho, O., Vanninen, E. J., Punnonen, K. R., Ylitalo, K., Tuomainen, P., and Peuhkurinen, K. J. (2007) Utility of plasma apelin and other indices of cardiac dysfunction in the clinical assessment of patients with dilated cardiomyopathy, Regul. Pept., 140, 178-184, doi: 10.1016/j.regpep.2006.12.004.
  67. Foldes, G., Horkay, F., Szokodi, I., Vuolteenaho, O., Ilves, M., Lindstedt, K. A., Mäyränpää, M., Sármán, B., Seres, L., Skoumal, R., Lakó-Futó, Z., deChâtel, R., Ruskoaho, H., and Tóth, M. (2003) Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure, Biochem. Biophys. Res. Commun., 308, 3, 480-485, doi: 10.1016/s0006-291x(03)01424-4.
  68. Ronkainen, V. P., Ronkainen, J. J., Hanninen, S. L., Leskinen, H., Ruas, J. L., Pereira, T., Poellinger, L., Vuolteenaho, O., and Tavi, P. (2007) Hypoxia inducible factor regulates the cardiac expression and secretion of apelin, FASEB J., 21, 1821-1830, doi: 10.1096/fj.06-7294com.
  69. Sheikh, A. Y., Chun, H. J., Glassford, A. J., Kundu, R. K., Kutschka, I., Ardigo, D., Hendry, S. L., Wagner, R. A., Chen, M. M., Ali, Z. A., Yue, P., Huynh, D. T., Connolly, A. J., Pelletier, M. P., Tsao, P. S., Robbins, R. C., and Quertermous, T. (2008) In vivo genetic profiling and cellular localization of apelin reveals a hypoxia-sensitive, endothelial-centered pathway activated in ischemic heart failure, Am. J. Physiol. Heart Circ. Physiol., 294, H88-H98, doi: 10.1152/ajpheart.00935.2007.
  70. Hashimoto, T., Kihara, M., Imai, N., Yoshida, S., Shimoyamada, H., Yasuzaki, H., Ishida, J., Toya, Y., Kiuchi, Y., Hirawa, N., Tamura, K., Yazawa, T., Kitamura, H., Fukamizu, A., and Umemura, S. (2007) Requirement of apelin-apelin receptor system for oxidative stress-linked atherosclerosis, Am. J. Pathol., 171, 1705-1712, doi: 10.2353/ajpath.2007.070471.
  71. Pitkin, S. L., Maguire, J. J., Kuc, R. E., and Davenport, A. P. (2010) Modulation of the apelin/APJ system in heart failure and atherosclerosis in man, Br. J. Pharmacol., 160, 1785-1795, doi: 10.1111/j.1476-5381.2010.00821.x.
  72. Peltonen, T., Napankangas, J., Vuolteenaho, O., Ohtonen, P., Soini, Y., Juvonen, T., Satta, J., Ruskoaho, H., and Taskinen, P. (2009) Apelin and its receptor APJ in human aortic valve stenosis, J. Heart Valve Dis., 18, 644-652.
  73. Leeper, N. J., Tedesco, M. M., Kojima, Y., Schultz, G. M., Kundu, R. K., Ashley, E. A., Tsao, P. S., Dalman, R. L., and Quertermous, T. (2009) Apelin prevents aortic aneurysm formation by inhibiting macrophage inflammation, Am. J. Physiol. Heart Circ. Physiol., 296, H1329-H1335, doi: 10.1152/ajpheart.01341.2008.
  74. Tiani, C., Garcia-Pras, E., Mejias, M., de Gottardi, A., Berzigotti, A., Bosch, J., and Fernandez, M. (2009) Apelin signaling modulates splanchnic angiogenesis and portosystemic collateral vessel formation in rats with portal hypertension, J. Hepatol., 50, 296-305, doi: 10.1016/j.jhep.2008.09.019.
  75. Principe, A., Melgar-Lesmes, P., Fernandez-Varo, G., del Arbol, L. R., Ros, J., Morales-Ruiz, M., Bernardi, M., Arroyo, V., and Jiménez, W. (2008) The hepatic apelin system: a new therapeutic target for liver disease, Hepatology, 48, 1193-1201, doi: 10.1002/hep.22467.
  76. Kalin, R. E., Kretz, M. P., Meyer, A. M., Kispert, A., Heppner, F. L., and Brändli, A. W. (2007) Paracrine and autocrine mechanisms of apelin signaling govern embryonic and tumor angiogenesis, Dev. Biol., 305, 599-614, doi: 10.1016/j.ydbio.2007.03.004.
  77. Sorli, S. C., Le Gonidec, S., Knibiehler, B., and Audigier, Y. (2007) Apelin is a potent activator of tumour neoangiogenesis, Oncogene, 26, 7692-7699, doi: 10.1038/sj.onc.1210573.
  78. Eyries, M., Siegfried, G., Ciumas, M., Montagne, K., Agrapart, M., Lebrin, F., and Soubrier, F. (2008) Hypoxia-induced apelin expression regulates endothelial cell proliferation and regenerative angiogenesis, Circ. Res., 103, 432-440, doi: 10.1161/circresaha.108.179333.
  79. Kidoya, H., Naito, H., and Takakura, N. (2010) Apelin induces enlarged and nonleaky blood vessels for functional recovery from ischemia, Blood, 115, 3166-3174, doi: 10.1182/blood-2009-07-232306.
  80. Zeng, X. J., Zhang, L. K., Wang, H. X., Lu, L. Q., Ma, L. Q., and Tang, C. S. (2009) Apelin protects heart against ischemia/reperfusion injury in rat, Peptides, 30, 1144-1152, doi: 10.1016/j.peptides.2009.02.010.
  81. Rastaldo, R., Cappello, S., Folino, A., Berta, G. N., Sprio, A. E., Losano, G., Samaja, M., and Pagliaro, P. (2011) Apelin-13 limits infarct size and improves cardiac postischemic mechanical recovery only if given after ischemia, Am. J. Physiol. Heart Circ. Physiol., 300, H2308-H2315, doi: 10.1152/ajpheart.01177.2010.
  82. Simpkin, J. C., Yellon, D. M., Davidson, S. M., Lim, S. Y., Wynne, A. M., and Smith, C. C. (2007) Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemia- reperfusion injury, Basic Res. Cardiol., 102, 518-528, doi: 10.1007/s00395-007-0671-2.
  83. Azizi, Y., Faghihi, M., Imania, A., Roghanib, M., and Nazari, A. (2013) Post-infarct treatment with [Pyr1]-apelin-13 reduces myocardial damage through reduction of oxidative injury and nitric oxide enhancement in the rat model of myocardial infarction, Peptides, 46, 76-82, doi: 10.1016/j.peptides.2013.05.006.
  84. Yang, S., Li, H., Tang, L., Ge, G., Ma, J., Qiao, Z., Liu, H., and Fang, W. (2015) Apelin-13 Protects the Heart against Ischemia-Reperfusion Injury through the RISK-GSK-3-MPTP Pathway, Arch. Med. Sci., 11, 1065-1073, doi: 10.5114/aoms.2015.54863.
  85. Pisarenko, O. I., Shulzhenko, V. S., Studneva, I. M., Serebryakova, L. I., Pelogeykina, Y. A., and Veselova, O. M. (2015) Signaling pathways of a structural analogue of apelin-12 involved in myocardial protection against ischemia/reperfusion injury, Peptides, 73, 67-76, doi: 10.1016/j.peptides.2015.09.001.
  86. An, S., Wang, X., Shi, H., Zhang, X., Meng, H., Li, W., Chen, D., and Ge, J. (2020) Apelin protects against ischemia-reperfusion injury in diabetic myocardium via Inhibiting apoptosis and oxidative stress through PI3K and P38-MAPK signaling pathways, Aging, 12, 25120-25137, doi: 10.18632/aging.104106.
  87. Kleinz, M. J., and Baxter, G. F. (2008) Apelin reduces myocardial reperfusion injury independently of PI3K/Akt and P70S6 kinase, Regul. Pept., 146, 271-277, doi: 10.1016/j.regpep.2007.10.002.
  88. Smith, C. C., Mocanu, M. M., Bowen, J., Wynne, A. M., Simpkin, J. C., Dixon, R. A., Cooper, M. B., and Yellon, D. M. (2007) Temporal changes in myocardial salvage kinases during reperfusion following ischemia: studies involving the cardioprotective adipocytokine apelin, Cardiovasc. Drugs Ther., 21, 409-414, doi: 10.1007/s10557-007-6054-y.
  89. O'Carroll, A-M., Lolait, S. J., Harris, L. E., and Pope, G. R. (2013) The apelin receptor APJ: journey from an orphan to a multifaceted regulator of homeostasis, J. Endocrinol., 219, R13-R35, doi: 10.1530/joe-13-0227.
  90. Masri, B., Morin, N., Pedebernade, L., Knibiehler, B., and Audigier, Y. (2006) The apelin receptor is coupled to Gi1 or Gi2 protein and is differentially desensitized by apelin fragments, J. Biol. Chem., 281, 18317-18326, doi: 10.1074/jbc.M600606200.
  91. Kennedy, S. G., Kandel, E. S., Cross, T. K., and Hay, N. (1999) Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria, Mol. Cell. Biol., 19, 5800-5810, doi: 10.1128/MCB.19.8.5800.
  92. Pisarenko, O., Shulzhenko, V., Studneva, I., Serebryakova, L., and Veselova, O. (2017) 5-Hydroxydecanoate abolishes cardioprotective effects of a structural analogue of apelin-12 in ischemia/reperfusion injury, Int. J. Pept. Res. Ther., 23, 333-341, doi: 10.1007/s10989-016-9565-1.
  93. Miura, T., Tanno, M., and Sato, T. (2010) Mitochondrial kinase signaling pathways in myocardial protection from ischaemia/reperfusion-induced necrosis, Cardiovasc. Res., 88, 7-15, doi: 10.1093/cvr/cvq206.
  94. Chapman, N. A., Dupré, D. J., and Rainey, J. K. (2014) The apelin receptor: physiology, pathology, cell signalling, and ligand modulation of a peptide-activated class A GPCR, Biochem. Cell Biol., 92, 431-440, doi: 10.1139/bcb-2014-0072.
  95. Khan, T. A., Bianchi, C., Ruel, M., Voisine, P., and Sellke, F. W. (2004) Mitogen-activated protein kinase pathways and cardiac surgery, J. Thorac. Cardiovasc. Surg., 127, 806-811, doi: 10.1016/j.jtcvs.2003.04.001.
  96. Jia, Y. X., Pan, C. S., Zhang, J., Geng, B., Zhao, J., Gerns, H., Yang, J., Chang, J. K., Tang, C. S., and Qi, Y. F. (2006) Apelin protects myocardial injury induced by isoproterenol in rats, Regul. Pept., 133, 147-154, doi: 10.1016/j.regpep.2005.09.033.
  97. Foussal, C., Lairez, O., Calise, D., Pathak, A., Guilbeau-Frugieret, C., Valet, P., Parini, A., and Kunduzova, O. (2010) Activation of catalase by apelin prevents oxidative stress-linked cardiac hypertrophy, FEBS Lett., 584, 2363-2370, doi: 10.1016/j.febslet.2010.04.025.
  98. Rastaldo, R., Cappello, S., Folino, A., and Losano, G. (2011) Effect of apelin-apelin receptor system in postischaemic myocardial protection: a pharmacological postconditioning tool? Antioxid. Redox Signal., 14, 909-922, doi: 10.1089/ars.2010.3355.
  99. Macaluso, N. J., and Glen, R. C. (2010) Exploring the ‘RPRL' motif of apelin-13 THROUGH molecular simulation and biological evaluation of cyclic peptide analogues, Chem. Med. Chem., 5, 1247-1253, doi: 10.1002/cmdc.201000061.
  100. Hamada, J., Kimura, J., Ishida, J., Kohda, T., Morishita, S., Ichihara, S., and Fukamizu, A. (2008) Evaluation of novel cyclic analogues of apelin, Int. J. Mol. Med., 22, 547-552, doi: 10.3892/ijmm_00000054.
  101. Wang, W., McKinnie, S. M., Patel, V. B., Haddad, G., Wang, Z., Zhabyeyev, P., Das, S. K., Basu, R., McLean, B., Kandalam, V., Penninger, J. M., Kassiri, Z., Vederas, J. C., Murray, A. G., and Oudit, G. Y. (2013) Loss of apelin exacerbates myocardial infarction adverse remodeling and ischemia-reperfusion injury: therapeutic potential of synthetic apelin analogues, J. Am. Heart. Assoc., 2, e000249, doi: 10.1161/JAHA.113.000249.
  102. Jia, Z. Q., Hou, L., Leger, A., Wu, I., Kudej, A. B., Stefano, J., Jiang, C., Pan, C. Q., and Akita, G. Y. (2012) Cardiovascular effects of a PEGylated apelin, Peptides, 38, 181-188, doi: 10.1016/j.peptides.2012.09.003.
  103. Iturrioz, X., Alvear-Perez, R., De Mota, N., Franchet, C., Guillier, F., Leroux, V., Dabire, H., Le Jouan, M., Chabane, H., Gerbier, R., Bonnet, D., Berdeaux, A., Maigret, B., Galzi, J. L., Hibert, M., and Llorens-Cortes, C. (2010) Identification and pharmacological properties of E339-3D6, the first nonpeptidic apelin receptor agonist, FASEB J., 24, 1506-1517, doi: 10.1096/fj.09-140715.
  104. Murali, S., and Aradhyam, G. K. (2023) Structure-function relationship and physiological role of apelin and its G protein coupled receptor, Biophys. Rev., 15, 127-143, doi: 10.1007/s12551-023-01044-x.
  105. Iturrioz, X., Gerbier, R., Leroux, V., Alvear-Perez, R., Maigret, B., and Llorens-Cortes, C. (2010) By interacting with the C-terminal Phe of apelin, Phe255 and Trp259 in helix VI of the apelin receptor are critical for internalization, J. Biol. Chem., 285, 32627-32637, doi: 10.1074/jbc.M110.127167.
  106. Pitkin, S., Macaluso, N., Maguire J., Glen, R., and Davenport, A. (2009) Role for apelin in human atherosclerosis and discovery of novel agonist for its receptor APJ, Proc. Br. Pharmacol. Soc., URL: http://www.pa2online.org/abstracts/Vol7Issue4abst027P.pdf.
  107. Macaluso, N. J., Pitkin, S. L., Maguire, J. J., Davenport, A. P., and Glen, R. C. (2011) Discovery of a competitive apelin receptor (APJ) antagonist, Chem. Med. Chem., 6, 1017-1023, doi: 10.1002/cmdc.201100069.
  108. Sidorova, M. V., Azmuko, A. A., Pal'keeva, M. E., Molokoedov, A. S., and Bushuev, V. N. (2012) Synthesis and cardioprotective properties of apelin-12 and its structural analogs [in Russian], Bioorg. Khim., 38, 40-51, doi: 10.1134/s1068162012010177.
  109. Молокоедов А. С., Беспалова Ж. Д., Пелогейкина Ю. А., Азьмуко А. А., Масенко В. П., Писаренко О. И., Шульженко В. С., Терещенко С. Н., Сидорова М. В., Палькеева М. Е. (2012) Додекапептиды, обладающие кардиопротекторными свойствами, Патент РФ № 2457216 (27.07.2012).
  110. Филатова М. П., Крит Н. А., Комарова О. М., Орехович В. И., Рейссманн З., Лиепиня И. Т., Никифорович Г. В. (1986) Синтез и исследование конформационно ограниченных аналогов пептидных ингибиторов ангиотензинпревращающего фермента, Биоорг. Хим., 12, 59-70.
  111. Janecka, A., Kruszynski, R., Fichna, J., Kosson, P., and Janecki, T. (2006) Enzymatic degradation studies of endomorphin-2 and its analogs containing N-methylated amino acids, Peptides., 27, 131-135, doi: 10.1016/j.peptides.2005.06.015.
  112. Pisarenko, O., Shulzhenko, V., Studneva, I., Pelogeykina, Yu., Timoshin, A., Anesia, R., Valet, P., Parini, A., and Kunduzova, O. (2015) Structural apelin analogues: mitochondrial ROS inhibition and cardiometabolic protection in myocardial ischaemia-reperfusion injury, Br. J. Pharmacol., 172, 2933-2945, doi: 10.1111/bph.13038.
  113. Pisarenko, O. I., Lankin, V. Z., Konovalova, G. G., Serebryakova, L. I., Shulzhenko, V. S., Timoshin, A. A., Tskitishvili, O. V., Pelogeykina, Y. A., and Studneva, I. M. (2014) Apelin-12 and its structural analog enhance antioxidant defense in experimental myocardial ischemia and reperfusion, Mol. Cell. Biochem., 391, 241-250, doi: 10.1007/s11010-014-2008-4.
  114. Pelogeykina, Y. A., Konovalova, G. G., Pisarenko, O. I., and Lankin, V. Z. (2015) Antioxidant action of apelin-12 peptide and its structural analog in vitro, Bull. Exp. Biol. Med., 159, 604-606, doi: 10.1007/s10517-015-3024-4.
  115. Pisarenko, O. I., Shulzhenko, V. S., Pelogeykina, Y. A., and Studneva, I. M. (2015) Enhancement of crystalloid cardioplegic protection by structural analogs of apelin-12, J. Surg. Res., 194, 18-24, doi: 10.1016/j.jss.2014.11.007.
  116. Pisarenko, O. I., and Studneva, I. M. (2023) Modified APJ receptor peptide ligands as postconditioning drugs in myocardial ischaemia/reperfusion injury, Int. J. Pept. Res. Ther., 29, 23, doi: 10.1007/s10989-023-10498-2.
  117. Tao, J., Zhu, W., Li, Y., Xin, P., Li, J., Liu, M., Li, J., Redington, A. N., and Wei, M. (2011) Apelin-13 protects the heart against ischemia-reperfusion injury through inhibition of ER-dependent apoptotic pathways in a time-dependent fashion, Am. J. Physiol. Heart Circ. Physiol., 301, H1471-H1486, doi: 10.1152/ajpheart.00097.2011.
  118. Hausenloy, D. J., and Yellon, D. M. (2007) Preconditioning and postconditioning: united at reperfusion, Pharmacol. Ther., 116, 173-191, doi: 10.1016/j.pharmthera.2007.06.005.
  119. Sidorova, M., Studneva, I., Bushuev, V., Pal'keeva, M., Molokoedov, A., Veselova, O., Ovchinnikov, M., and Pisarenko, O. (2020) [MeArg1, NLe10]-apelin-12: Optimization of solid-phase synthesis and evaluation of biological properties in vitro and in vivo, Peptides, 129, 170320, doi: 10.1016/j.peptides.2020.170320.

© Russian Academy of Sciences, 2023

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>